Marken Inaugurates New Argentina Pharmaceutical Service Depot
Marken continues their expansion of services in Latin America, by augmenting their GMP Compliant depot network with the newly purpose-built Buenos Aires facility.
“The expansion of our services in Latin America enables our clients to better recruit in treatment naïve populations and work with previously unreachable investigator sites, assuring quality and regulatory documentation through the entire supply chain.” said Wes Wheeler, Marken’s Chief Executive Officer.
Marken is implementing their stated plan and aims to build the most advanced, fit for purpose clinical distribution network to serve the pharmaceutical community. The new Argentina depot builds on Marken’s current Latin America business, and enables the company to grow from its life sciences logistics platform. Marken is developing further depot facilities in Europe, Asia and the Americas.
The Argentina depot joins Marken’s Mexico and Singapore depots offering the full range of temperature controlled storage capabilities including: controlled ambient, refrigerated (2º-8ºC), frozen (-20ºC) as well as a secured area for controlled substances. Each of Marken’s depots provides drug and equipment distribution solutions including: Pick & Pack, relabeling services, reverse logistics, reconciliation and certified destruction. Additionally the network manages specimen kit distribution, interim specimen storage and management.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
